Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: A systematic review and meta-analysis

Heart

Volumn 100, Issue 4, 2014, Pages 324-335

  Providência, Rui ^a,b   Albenque, Jean Paul ^a   Combes, Stephane ^a   Bouzeman, Abdeslam ^a   Casteigt, Benjamin ^a   Combes, Nicolas ^a   Narayanan, Kumar ^c   Marijon, Eloi ^c,d   Boveda, Serge ^a  

^a CLINIQUE PASTEUR   (France)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CATHETER ABLATION; HUMANS; PREOPERATIVE CARE; THROMBOEMBOLISM; TREATMENT OUTCOME; WARFARIN;

EID: 84893518420     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2013-304386     Document Type: Article

References (31)

1. Chen LY, Shen WK. Epidemiology of atrial fibrillation: a current perspective. Heart Rhythm 2007;4(3 Suppl):S1-6.
2. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996;27:1760-4. (Pubitemid 26332500)
3. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm 2011;8:157-76.
4. Crawford T, Oral H. Current status and outcomes of catheter ablation for atrial fibrillation. Heart Rhythm 2009;6(12 Suppl):S12-17.
5. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
6. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
7. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
8. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Heart Rhythm 2012;9:632-96.e21.
9. Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 2012;59:1168-74.
10. Menzies D. Systematic reviews and meta-analyses. Int J Tuberc Lung Dis 2011;15:582-93.
11. Moher D, Liberati A, Tetzlaff J, et al. PRISMA Group: preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9.
12. Verhagen AP, de Vet HC, de Bie RA, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998;51:1235-41. (Pubitemid 29009523)
13. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical-epidemiology/oxford.htm (accessed 28 Jun 2013).
14. Sorgente A, Chierchia GB, de Asmundis C, et al. Complications of atrial fibrillation ablation: when prevention is better than cure. Europace 2011;13:1526-32.
15. Bassiouny M, Saliba W, Rickard J, et al. Use of dabigatran for peri-procedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol. 2013;6:460-6.
16. Haines DE, Mead-Salley M, Salazar M, et al. Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation. J Interv Card Electrophysiol. 2013. [Epub ahead of print]
17. Kaseno K, Naito S, Nakamura K, et al. Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. Circ J 2012;76:2337-42.
18. Kim JS, She F, Jongnarangsin K, et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm 2013;10:483-9.
19. Maddox W, Kay GN, Yamada T, et al. Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. J Cardiovasc Electrophysiol 2013. doi: 10.1111/jce.12143. [Epub ahead of print]
20. Nin T, Sairaku A, Yoshida Y, et al. A Randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. Pacing Clin Electrophysiol 2013;36:172-9.
21. Snipelisky D, Kauffman C, Prussak K, et al. A comparison of bleeding complications post-ablation between warfarin and dabigatran. J Interv Card Electrophysiol 2012;35:29-33.
22. Yamaji H, Murakami T, Hina K, et al. Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation. Clin Drug Investig 2013;33:409-18.
23. Bernard M, Brabham W, Netzler P, et al. Comparison of atrial fibrillation ablation bleeding and thrombotic complications with dabigatran, rivaroxaban and warfarin. J Am Coll Cardiol 2013;61:(Suppl):E276. Abstract.
24. Ichiki H, Oketani N, Iriki Y, et al. The comparison of warfarin and dabigatran in the incidence of asymptomatic cerebral micro thromboembolism after AF ablation. Circulation 2012;126(21 Suppl 1):A9301. Abstract.
25. Mendoza I, Helguera M, Baez-Escudero J, et al. Atrial fibrillation ablation on uninterrupted anticoagulation with dabigatran versus warfarin. Heart Rhythm 2012;9(5 Suppl 1):S270-1. Abstract.
26. Pavaci H, Reents T, Ammar S, et al. Safety and efficacy of dabigatran in patients undergoing left atrial ablation procedures: a case-matched analysis. Eur Heart J 2012;33(Abstract Supplement):60-1. Abstract.
27. Rowley CP, Bradford NS, Bernard ML, et al. Complications of atrial fibrillation ablation in patients anticoagulated with dabigatran compared to warfarin. Heart Rhythm 2012;9(5 Suppl 1):S201. Abstract.
28. Piccini JP, Sinner MF, Greiner MA, et al. Outcomes of Medicare beneficiaries undergoing catheter ablation for atrial fibrillation. Circulation 2012; 126:2200-7.
29. Hussein AA, Martin DO, Saliba W, et al. Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm 2009;6:1425-9.
30. Winkle RA, Mead RH, Engel G, et al. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol 2012;23:264-8.
31. Ross Southworth M, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013;368:1272-4.